Engflag

Azicin

Quick links to important sections

Azicin

Azicin_DE

Method of action: Bactericidal, Ophthalmologicals

Treatment option: Lyme Disease, Bronchitis, Community Acquired Pneumonia, Impetigo, Infection, Infection,Soft Tissue, Middle Ear Infection, COPD,Acute, Pneumonia, Sinus Infection

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azicin

Quick Facts

Property Description
Active ingredient Azithromycin
Form Oral Solids, Oral Liquids, Sterile Injectable Solution
Pharmacological class Macrolide Antibiotic (Azalide Subclass)
General purpose Treating systemic bacterial infections
Origin Semi-synthetic compound

What Type of Medicine is Azicin, and Where Does It Come From?

Azicin is defined as a systemic antibacterial agent used exclusively to resolve infections caused by susceptible bacteria, and its active component is the substance Azithromycin. Azithromycin is officially classified within the Macrolide antibiotic class, specifically belonging to the Azalide subclass. This classification is based on the drug's core chemical structure, which incorporates a nitrogen atom into the macrolide ring, differentiating it from older macrolides. The active ingredient is a semi-synthetic compound; it is chemically synthesized using a natural precursor to achieve specific, optimized therapeutic properties, such as enhanced stability and absorption. The Azalide structure is clinically recognized for contributing to the medicine's longer half-life, which often simplifies the patient's treatment regimen.

Azicin's Composition, Available Forms, and General Purpose

Azicin is a single-ingredient product, containing only Azithromycin as the active pharmaceutical component. Azithromycin is supplied in various dosage forms, which include oral solid forms (tablets or capsules), oral liquid forms (suspensions), and sterile injectable solutions for intravenous use. The overall general therapeutic purpose of Azicin is to provide a reliable means of suppressing the proliferation of susceptible bacteria throughout the body. By inhibiting the bacteria's ability to manufacture essential proteins, the medicine effectively stops the infection from getting worse by preventing bacteria from growing. This structural advantage helps ensure the drug remains active at the site of infection for a longer duration, providing targeted relief for conditions like bacterial respiratory tract infections.

Regulatory References

  1. Azithromycin - MeSH - NIH

What side effects are possible with Azicin?

Possible Side Effects and Safety Information

Azicin (azithromycin) is associated with a range of adverse reactions, which are officially documented and classified by frequency and affected body system. All safety information is derived from government regulatory documents, such as the FDA and EMA.

Common and Expected Adverse Reactions

The most commonly reported side effects, based on clinical trials, primarily involve the Gastrointestinal System. These reactions are generally mild to moderate and include Diarrhea, Nausea, Abdominal Pain, Vomiting, and Headache.

Serious Adverse Reactions

The regulatory label details rare but clinically significant adverse reactions that require immediate attention:

  • Cardiovascular Risks: Azithromycin can cause QT interval prolongation and lead to serious arrhythmias, including Torsades de Pointes.
  • Liver Problems: Cases of Hepatitis, Cholestatic Jaundice, and, rarely, Fatal Hepatic Failure have been documented.
  • Hypersensitivity and Skin Reactions: Serious allergic reactions, such as Anaphylaxis and severe skin conditions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), may occur.

Population-Specific Safety Considerations

Specific caution and restrictions apply to certain patient groups:

Patient Group Regulatory Safety Note
Prior Hepatic Dysfunction Contraindicated if associated with previous azithromycin use.
Severe Renal Impairment Use with caution (GFR < 10 mL/min) due to increased systemic exposure.
Neonates (under 42 days) Documented cases of Infantile Hypertrophic Pyloric Stenosis (IHPS).
Elderly Patients May be more susceptible to QT prolongation risk.

Discontinuation of Azicin is officially mandated if signs of significant liver dysfunction or severe skin reactions occur. The risk of acute cardiovascular events may be highest during the first five days of use.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes Azicin overdose primarily through two domains: the nature of the symptoms and the potential for serious cardiac toxicity.

Documented Overdose Presentations

Symptoms reported following the ingestion of doses higher than recommended are typically similar to the common adverse reactions seen at therapeutic doses. These may include nausea, vomiting, and diarrhea. The management of an overdose is generally symptomatic and supportive, meaning care is focused on treating the specific symptoms that appear and maintaining vital functions.

Critical Risk and Emergency Action

The most serious risk associated with an overdose, as highlighted in official documents, is the potential for prolongation of the QT interval. This electrical change in the heart can lead to a potentially fatal heart rhythm abnormality, such as Torsades de Pointes. This risk is particularly relevant for individuals with pre-existing cardiovascular conditions or those taking other QT-prolonging medications.

Because of the potential for this serious cardiac risk, it is essential to seek immediate medical attention if an overdosage is suspected. Call the Poison Control Center or emergency services right away. Emergency medical help is specifically required if the affected individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. These official statements define the core of the overdose profile and the urgent need for medical evaluation.

Therapeutic Uses of Azicin

What Azicin Treats: Main Uses and Benefits

Azicin, whose active ingredient is Azithromycin, is a systemic antibacterial used for managing conditions involving inflammatory or irritative processes related to bacterial presence. It is commonly applied across domains where additional symptomatic support is needed, with a focus on symptoms that interfere with daily functioning. It is relevant for easing discomfort related to infections across several body systems, including the respiratory tract, skin, and reproductive organs.

The medication is commonly used across conditions presenting with acute episodes, including community-acquired pneumonia, acute exacerbations of chronic bronchitis, bacterial sinusitis, acute otitis media, and uncomplicated bacterial infections of the skin and genital tract. It is applied in addressing symptom clusters that may become intense or disruptive, including persistent coughing, breathing distress, severe throat pain, and localized swelling or discharge. Applied during phases of increased distress or discomfort, the medication contributes to easing the overall symptom load and supports the patient during difficult episodes by easing distress.

Quick Fact: Relief for Acute Infection Symptoms

Focus Area Symptom Management Role
Respiratory Distress Helps ease severe coughing and breathing discomfort.
Localized Inflammation Relevant for managing pain and swelling in ear and skin infections.
Systemic Symptoms Contributes to easing the overall symptom load of fever and malaise.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Azicin?

Azicin is strictly contraindicated in patients who have a known hypersensitivity to the active ingredient, azithromycin, or to any other macrolide or ketolide antibiotic. Use is also prohibited for patients with a history of cholestatic jaundice or hepatic dysfunction explicitly linked to prior azithromycin therapy.

Conditional Use and Restrictions

Population Group Eligibility Status
Severe Organ Impairment Caution is required for patients with severe renal impairment (GFR < 10 mL/min) or significant hepatic disease; the medicine is generally not recommended for severe liver disease (EMA).
Cardiac/Neuromuscular Conditions Use requires caution in patients with known QT interval prolongation or a history of Torsades de Pointes. Caution is also advised for those with Myasthenia Gravis, as symptoms may be exacerbated.

Age and Physiological Limitations

  • Infants: Safety and effectiveness are not established for most uses in infants under six months of age.
  • Older Adults: Generally eligible but may be more susceptible to cardiac arrhythmias; caution is advised.
  • Pregnancy: Use is permitted only if clearly needed and when the benefit outweighs the potential risk.
  • Lactation: Caution is advised, as the medicine passes into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Azicin (Azithromycin) interactions are officially defined by pharmacodynamic risks, pharmacokinetic alterations, and administration constraints detailed in government regulatory documents.

Documented Interaction Patterns

Classification Official Regulatory Constraint
Contraindicated Combinations Co-administration with Ergot derivatives (e.g., Ergotamine) is strictly prohibited due to the theoretical risk of ergotism.
QT Risk Combining with other QT-prolonging substances (e.g., Amiodarone, Pimozide) is a documented risk factor for ventricular arrhythmias (Torsades de Pointes).
Pharmacokinetic Effects Azicin is documented as a P-glycoprotein (P-gp) inhibitor, which can increase the systemic exposure of substrates like Digoxin. Co-administration with Nelfinavir is officially stated to increase Azicin's own Cmax and AUC.
Anticoagulants Co-administration with Warfarin may increase coagulation times, necessitating the regulatory monitoring of INR.

Administration Constraints and Specific Products

Interaction Type Requirement/Effect
Timing-based Rule Aluminum- or magnesium-containing Antacids must not be taken simultaneously with Azicin; doses must be separated by approximately 2 hours to prevent reduced peak plasma concentration.
Food Interaction Food officially increases the Cmax of both oral tablets (by 23%) and oral suspension (by 56%), while the overall systemic exposure (AUC) remains unchanged.
Population Note Renal Impairment (GFR 10 to 80 mL/min) is associated with a minor increase in Azicin’s systemic exposure (Cmax and AUC), as noted in official prescribing information.

The drug's interaction profile establishes constraints focused on cardiac safety and the need for coagulation monitoring, alongside specific timing requirements for certain mineral-containing products.

Mechanism of Action

Mechanism of Action: Azicin (Azithromycin)

Azicin operates through two key mechanistic domains: the inhibition of bacterial protein synthesis and the modulation of host inflammatory pathways.

Targeting the Bacterial Ribosome and Protein Manufacturing

The primary mechanism involves the inhibition of bacterial protein synthesis. Azicin specifically binds to the 50S ribosomal subunit of the 70S ribosome , physically obstructing the nascent peptide exit tunnel. This action immediately halts the elongation and translocation of polypeptide chains, preventing the organism from assembling structural and functional proteins necessary for cellular operation. The result is a cessation of bacterial growth and replication (bacteriostasis), which establishes a reduction in microbial proliferation across affected tissues.

Intracellular Delivery and Immunomodulatory Effects

This feature is the drug's high affinity for host phagocytes (immune cells), resulting in intracellular accumulation and transport. These immune cells then transport high concentrations of the active ingredient directly to the affected tissues, establishing sustained local drug concentration. This mechanism is further complemented by an immunomodulatory effect, where Azicin dampens the production of certain pro-inflammatory cytokines and alters neutrophil dynamics, which modifies the host's inflammatory cascade.

Dosage and Administration Information

How to Use Azicin: Official Administration Guidelines

Azicin (Azithromycin) is officially administered via the Oral route (tablets, capsules, or suspension) or the Intravenous (IV) route (injectable solution). The dosing regimen is highly structured and varies based on the total treatment duration. Common standard adult regimens include a 3-day course of 500 mg taken once daily, or a 5-day course beginning with 500 mg on Day 1 followed by 250 mg once daily on Days 2 through 5. For certain acute infections, a single 1 gram or 2 gram oral dose is prescribed. The medicine is generally taken as a single dose once every 24 hours.

Administration and Timing Constraints

Instruction Official Requirement
Standard Oral Forms May be taken with or without food.
Extended-Release Suspension Must be taken on an empty stomach (1 hour before or 2 hours after food).
IV Administration Must be given as a slow infusion over 1 to 3 hours; prohibited as a bolus or intramuscular injection.
Pediatric Dosing Requires a weight-based calculation (mg/kg) for children weighing less than 45 kg.
Missed Dose Should be taken immediately upon recollection, with subsequent doses taken at the next scheduled time, ensuring the full prescribed course is completed.

These official instructions standardize the administration method, required dose amounts, and timing specifications, ensuring proper procedural use. No dose adjustment is typically required for older adults or patients with mild-to-moderate renal impairment.

Recent Clinical Evidence

Research concerning Azicin (azithromycin) primarily focuses on its evaluation in Randomized Controlled Trials (RCTs) and systematic reviews. This body of evidence is used by health authorities to understand how Azicin has been observed in conditions characterized by acute or disruptive episodes linked to bacterial presence.

Evidence for Use in Acute Respiratory and Ear Infections

Studies have extensively explored Azicin's use in conditions such as community-acquired pneumonia (CAP) and acute exacerbation of chronic bronchitis (AECB). Researchers conducted short-term RCTs, including adults and children, that examined clinical success, measured by changes in outcomes related to fever, cough, and breathing discomfort, as well as microbiological eradication. For AECB, studies monitored outcomes related to acute respiratory symptoms; however, existing studies provide limited insight into the long-term patterns related to the underlying chronic disease progression after the acute phase is completed.

Research Findings for Genital and Skin Infections

Azicin was evaluated in clinical trials for managing uncomplicated bacterial infections of the genital tract, specifically those caused by Chlamydia trachomatis. These trials, which primarily used a single-dose regimen on adults and adolescents, examined microbiological eradication, a key outcome measure tracked in the studies. Data show patterns related to the achievement of microbiological cure rates that contribute to Azicin's presence in established treatment protocols.

Context of Long-Term Studies and Extended Observation

A separate body of research has explored the use of Azicin over extended periods—sometimes six months to multiple years—in patients with chronic lung conditions like bronchiectasis and cystic fibrosis. These long-term studies, often placebo-controlled, monitored functional measures and outcomes describing episodic changes, such as the frequency of exacerbations. Long-term studies also included the monitoring of potential changes that may be associated with extended use.

Evidence in Special Patient Populations

Research has examined the use of Azicin in children for conditions like acute otitis media, applying in settings evaluating short-term or episodic symptom patterns. Data for certain groups remain insufficient or highly specialized. For instance, the evidence for use in patients with complex, severe underlying health conditions requires reference to existing trial data which primarily reflects the general populations studied.

Understanding Evidence Gaps and Areas of Uncertainty

While significant research exists, a key limitation noted in research that was observed in some studies is the increased risk of selecting for bacterial resistance, particularly with repeated or long-term use. Additionally, follow-up durations were limited in many acute studies, meaning that long-term effects are not fully established regarding the durability of response. Findings describe group patterns, not individual predictions.

How should Azicin be stored and disposed of?

Storage and Disposal Requirements

The official labeling for Azicin (Azithromycin) defines strict requirements for storage, handling, and disposal based on dosage form.

Storage Conditions

Dosage Form Temperature Requirement Protection Requirements
Tablets/Dry Powder Controlled room temp. (15 C to 30 C) Protect from heat, moisture, and light
Oral Suspension Do not freeze Discard standard suspension after 10 days

All forms of this medication must be kept in their original container, tightly closed, and stored out of the sight and out of reach of children. The integrity of the drug is dependent on avoiding excess heat, moisture, and light exposure.

Disposal

To dispose of unused or expired Azicin, government guidance specifies that it should not be flushed down the toilet or poured down a drain. Instead, the medication should be mixed with an undesirable substance, such as dirt or used coffee grounds, placed into a sealed bag, and discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagBangladesh

flagPakistan

Equivalent of Azicin found in:

A-Z Index: